Home
Dashboard
Bookmarks
Portfolios
ExplorerFunds
Equities
Library
Insights
Pinindices
MobileApp Store
Android

Cancer

Healthcare Innovation ETFsDeeply transformative healthcare expectations or ever hopeful promises of basic research advance
Healthcare Innovation ETFs
  • 41.6%
  • 9
Biotechnology - Genetic Revolutions Small- and Mid-Cap biotech firms at the forefront of DNA manipulations and gene therapies
Biotechnology - Genetic Revolutions
  • 50.5%
  • 42
Next 60 MidCap Biotech FirmsWith market capitalizations between $2bn and $10bn, the performance of the midcap biotech selection has gained momentum
Next 60 MidCap Biotech Firms
  • 99.9%
  • 61
Biotech Movers - a January '23 SurpriseReversal of the negative 2022 trend of biotech firms has been notable - the industry remains volatile but investments could be rewarding
Biotech Movers - a January '23 Surprise
  • 27.6%
  • 17
30 Biotech LargeCap Firms The biotech firms, with market capitalization exceeding $10 billion, are strong contributors to the industry's performance - Momentum is indicative of the sector's resilience
30 Biotech LargeCap Firms
  • 54.5%
  • 30
Cancer, Rare Diseases & Cell TherapiesResearch Breakthrough and Pricing Challenges
Cancer, Rare Diseases & Cell Therapies
  • 44.2%
  • 26
  • 2
Next 60 Small-Cap BiotechSelection of small market cap biotech firms, below $2 billion
Next 60 Small-Cap Biotech
  • 63.9%
  • 60